editoral Videos (listed by category)
ESMO 2024
ESMO 2024: Prof. Sibylle Loibl Discusses PENELOPE-B Trial Results
Watch as Prof. Sibylle Loibl, PI of the PENELOPE-B trial, presents the final overall survival and subgroup analyses for lobular breast cancer patients at ESMO 2024. Gain a detailed overview of the study's key findings and implications.
ESMO 2024 - Daily RECAP day 3
Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.
ESMO 2024: Dr. Jean-Philippe Spano - ESMO's Growth and Impact on Oncology Practice
Dr. Jean-Philippe Spano provides a brief history of ESMO's origins and its remarkable growth over the years. He reviews the latest data presented, with a special focus on contributions from his French colleagues and key international studies that have shaped clinical practice in breast cancer oncology.
ESMO 2024: Dr. Cristina Saura: Key ESMO Findings on Breast Cancer Trials & Breastfeeding Safety
Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.
ESMO 2024: Artificial Intelligence in Oncology with Amy Abernethy, MD, PhD
In this video,Dr. Amy Abernethy highlights the transformative potential of AI in oncology and stresses the need for safety and efficacy in patient care. She outlines three key trends essential for scaling AI in the field.
ESMO 2024: Dr. Erika Hamilton on Trastuzumab and HER2 Testing Insights
In this video, Dr. Erika Hamilton highlights the latest data on trastuzumab and HER2 testing presented at ESMO 2024. She provides valuable insights into recent advancements and their implications for treatment strategies in HER2-positive cancers.
ESMO 2024 - Daily RECAP day 2
In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.
ESMO 2024: Updates on ICARUS-BREAST01 with Dr. Barbara Pistilli
Dr. Barbara Pistilli, Head of the Breast Pathology Committee at Gustave Roussy, presents the promising results of the Phase II ICARUS-BREAST01 trial at ESMO 2024.
ESMO 2024 - Overall Survival Data from the KEYNOTE-522 Trial with Dr. Peter Schmid
Dr. Peter Schmid presents the long-awaited overall survival data for Pembrolizumab in early-stage triple-negative breast cancer. His insights provide a crucial update on the impact of this therapy, highlighting significant advancements in treatment outcomes.
ESMO 2024 - Daily RECAP day 1
Join Dr. Asselah, Dr. Younan and Dr. Ma as they review the day's highlights from ESMO 2024
ESMO 2024 - Global Speaker Series - Dr. Nancy Lin on ESMO LBA18: Trastuzumab deruxtecan (T-DXd) in patients with HER2+ advanced/mbc & DESTINYBreast-12 primary results
With Dr. Nancy Lin
ESMO 2024 - Global Speaker Series - Dr. Alnouri Highlights What to Expect at ESMO 2024: Advances in Breast Cancer
with Dr. Anwar Alnouri MD
ESMO 2024 - Global Speaker Series - De-escalation Strategies in HER2+ Early-Stage Breast Cancer with Dr. Carlos A. Gonzalez Nuñez MD
With Dr. Carlos A. Gonzalez Nuñez MD
ASCO 2024
ASCO 2024 - Global Speaker Series - Dr. Javier Cortés reviews key insights from the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts
Dr. Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain, reviews key insights from the recent ASCO meeting, focusing on the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts.
ASCO 2024 - Global Speaker Series - Dr. Erika P. Hamilton presents the compelling results from the Phase I trial of H3B-6545
Dr. Erika P. Hamilton delves into the evidence and insights from the trial, highlighting the potential impact on breast cancer treatment.
ASCO 2024 - Global Speaker Series - Exciting update on the overall survival data from the DESTINY-Breast03 trial
Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.
ASCO 20204 - Global Speaker Series - PALMARES-2 Study: Real-World Insights on CDK4/6 Inhibitors
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
ASCO 2024 - Global Speaker Series - Novel Additions to Breast Cancer Therapy: Insights from Dr. Laura Stewart Dominici
Dr. Dominici Chairs ASCO’s "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
ASCO 2024 - Global Speaker Series - Advancements in Breast Cancer Research: Insights from Dr. Shaheena Dawood
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, post MONARCH study and updated analysis from the innovaTV207 trial.
ASCO 2024 - Global Speaker Series - Advancements in AI for Breast Cancer Imaging with Dr. Maryellen Giger
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides
ASCO 2024 - MedTalk: Dr. Stephanie Wong on PARPi Eligibility in Women with Newly Diagnosed Invasive Breast Cancer
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
ASCO 2024 - Global Speaker Series: Dr. Judy-Anne Williams Chapman on Standardizing ER and PgR Quantitation in Breast Cancer
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
ASCO 2024 - Daily RECAP day2
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
ASCO 2024 - Dr. Jane Lowe Meisel Presents I-SPY2.2 Trial Results on Datopotamab Deruxtecan for High-Risk HER2-Negative Breast Cancer
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
ASCO 2024 - Dr. Matthew P. Goetz on the ELAINE 3 Study: Lasofoxifene and Abemaciclib in ER+/HER2- Advanced Breast Cancer
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
ASCO 2024 - Dr. Jean-Pierre Ayoub Reviews DESTINY-Breast06: Trastuzumab Deruxtecan's Impact on Progression-Free Survival
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
ASCO 2024 - Dr. Mark Basik Highlights TRICIA Study Results in Triple Negative Breast Cancer
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
ASCO 2024: Daily RECAP day 1 with Drs. Asselah and Ma
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.
ASCO 2024 : Global Speaker Series with Dr. Conte
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
ASCO 2024 : Global Speaker Series with Dr. Santa Maria
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
CLINICAL IMPACT Series
CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer
Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.
CLINICAL IMPACT - Ask the experts: Advancing Clinical Research in Breast Cancer
Insights into Phases, Endpoints and Patient-Centric Strategies with Dr. Jamil Asselah and Dr. Véronique Diéras
ESMO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Kim Ma
Insights & Innovations: Panel discussion on Patient-Reported Outcomes and AI in breast cancer
With Dr. Jamil Asselah, Dr. Tarek Hijal, Pr. Sylvie Lambert, Dr. Bertrand Lebouché & John Ioculano
ASCO 2023 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2023 data in Breast Cancer with Dr. Jamil Asselah, Dr. Nicholas Meti & Dr. Khashayar Esfahani
CLINICAL IMPACT - Genetic testing for breast cancer patients in Quebec: Why, how and whom?
Session moderated by Dr. Rami Younan, featuring Nathalie Bolduc, Genetic Counsellor and Dr. Julie Lemieux, Hematologist and Medical Oncologist.
SABCS 2022 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Sara Soldera and Dr. Julie Lemieux
ESMO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ESMO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Rami J. Younan & Dr. Nicholas Meti
ASCO 2022 Breast Cancer : Clinical Impact on Your Practice
Review of ASCO 2022 data in Breast Cancer with Dr. Jamil Asselah, Dr. Khashayar Esfahani & Dr. Isabelle Gingras
CLINICAL IMPACT SERIES: SABCS 2021 - Breast Cancer Review Expert Panel Discussion
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC, Dr. Rami Younan, MD, FRCSC, and Dr. Jamil Asselah, MD, FRCPC
CLINICAL IMPACT SERIES: SABCS 2021 - Metastatic Breast Cancer
Presentations review with Dr. Jamil Asselah, MD, FRCPC
CLINICAL IMPACT SERIES: SABCS 2021 - Neo Adjuvant Breast Cancer
Presentations review with Dr. Rami Younan, MD, FRCSC
CLINICAL IMPACT SERIES: SABCS 2021 - Adjuvant Breast Cancer for ER+ HER2-, and ER-
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC
Dr. Tarantino - DESTINY BREAST
Q4: What is the impact of DESTINY BREAST trial on triple-negative breast cancer?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q3: Any other AEs to be on a look out for?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?
Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial
SABCS 2023
SABCS 2023 Breast Cancer : Clinical Impact on Your Practice
Review of SABCS 2023 data in Breast Cancer with Dr. Rami Younan, Dr. Julie Lemieux & Dr. Kim Ma
SABCS 2023 : Global Speaker Series Dr. Sara A. Hurvitz
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
SABCS 2023 : Global Speaker Series Dr. Seema Khan
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
SABCS 2023 : Global Speaker Series Dr. Peter Schmid
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
SABCS 2023 : Global Speaker Series Dr. Hope S. Rugo
Essential findings of the INAVO120 primary analysis
SABCS 2023 : Global Speaker Series Dr. Shaheenah Dawood
Exploring Pioneering Initiatives: Tailoring Patient-Centric Solutions for a Diverse Cohort in the UAE
SABCS 2023 : Global Speaker Series Dr. Hatem Azim
Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy
SABCS 2023 : MedTalk Dr. Nagi S. El Saghir
Insights from the RIGHT Choice trial
SABCS 2023 : MedTalk Dr. Paolo Tarantino
Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
SABCS 2023 : Global Speaker Series Dr. Anne May
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
SABCS 2023 : Daily RECAP Day 4 - December 8th
Daily Review from SABCS 2023 with Dr. Jamil Asselah, Dr. Esfahani, and Dr. Tarantino.
SABCS 2023 : MedTalk Dr. Julie Lemieux
Neoadjuvant chemotherapy in invasive lobular carcinoma of the breast: A retrospective study on survival outcomes
SABCS 2023 : MedTalk Dr. Jean-Pierre Ayoub
Prognostic Impact of Adjuvant Trastuzumab for the Treatment of Localized Stage I Breast Cancer - Single Tertiary Center Experience
SABCS 2023 : Daily RECAP Day 3 Part 2 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Daily RECAP Day 3 Part 1 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : MedTalk Dr. Stephanie Wong
Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer
SABCS 2023 : MedTalk Dr. Mark Basik
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
SABCS 2023 : Global Speaker Series Dr. Eleftherios (Terry) P. Mamounas
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
SABCS 2023 : Daily Recap, December 6th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Global Speaker Series Dr. Claudio Vernieri
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
SABCS 2023 : MedTalk Nathalie Bolduc
Key points from the SABCS session on Prevention, early detection and interception
SABCS 2023 : Global Speaker Series Barbarra Segara
Screening for health related social needs, and now what? With Barbara Segarra-Vasquez DHSc
SABCS 2023 : Global Speaker Series Dr. Carlos A. Gonzalez Nuñez
Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL
SABCS 2023 : Daily Recap, December 5th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2022
SABCS - T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2+ MBC
Discussion with Dr. Sara Hurvitz, M.D.
SABCS - Racial Disparity in Pro-metastatic T-MEM Among Women With Residual BC After NAC
Discussion with Dr. Maja H. Oktay, M.D., Ph.D.
SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC
Discussion with Dr. Mafalda Oliveira, M.D., Ph.D.
SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation
Discussion with Pr. Per Karlsson, M.D.
SABCS 2022 - Race and Clinical Outcomes in the RxPONDER Trial
Discussion with Dr. Yara Abdou
ESMO 2022
ESMO 2022 - TROPiCS-02: Final results phase III study in MBC
Discussion with Prof. Hope S. Rugo, MD
ASCO 2022
ASCO 2022 - MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC
Discussion with Dr. Kevin Kalinski, MD, MS
ASCO 2022 - DESTINY-Breast04 trial in HER2-low unresectable and/or metastatic breast cancer
Pr. John Bartlett and Pr. David Cameron, MD, review the current results of DESTINY-Breast04 trial
Molecular Profiling; From prognosis to prediction – remaining questions
Scientific Presentation with Prof. John Bartlett
The success of ADCs raises questions about patient selection
Scientific Presentation with Prof. John Bartlett
AI Series
AI SERIES: Retrospective Overview Panel Discussion
Panel discussion with Faculty with Pr. Evelyne Yehudit Bischof, Professor Robert Clarke, Professor John FR Robertson
AI SERIES: Panel Discussion - Precision medicine in practice - diagnostic algorithms & geroncology
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES: Precision medicine in practice - diagnostic algorithms & geroncology
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel Discussion: A review of Precision medicine in cancer therapeutics - Hormone sensitive Breast Cancer and AI challenges
Discussion on Presentation by Professor John FR Robertson MD
AI SERIES - Precision medicine cancer therapeutics, HR sensitive BC and AI challenges
Presentation by Pr. John Robertson MD
AI SERIES - AI assisted drug development and repurposing in Breast Cancer
With Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Personalized vs precision medicine, clinical applicability
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Personalized vs precision medicine, clinical applicability
Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Do we need Artificial Intelligence for Precision Medicine?
Discussion on Presentation by Pr. Robert Clarke
AI SERIES - Do we need Artificial Intelligence for Precision Medicine?
Presentation by Pr. Robert Clarke Ph.D., D.Sc.
AACR 2022
AACR 2022: Recurrent NIB May Not Always Be Related to the Primary Lesion
Interview with Dr. Tanjina Kader, PhD
AACR 2022: AI Model Can Help Predict Adverse Events from New Drug Combinations
Interview with Pr. Bart Westerman, PhD
AACR 2022: New CAR T-cell Therapy for Solid Tumors
Interview with Pr. John Haanen, MD, Ph.D
COVID Impact
Expected medium- and long-term impact of the COVID-19 on Breast Cancer Treatment in Quebec
Interview with Dr Jamil Asselah
ESMO-2020 - Expected medium and long-term impact of the COVID-19 outbreak in Oncology
Presentation by Professor Guy Jerusalem
ESMO-2020 Q&A with Professor Guy Jerusalem on Expected medium and long-term impact of the COVID-19 outbreak in Oncology
with Professor Guy Jerusalem
A Global Collaborative study looking at the Impact of COVID-19 Pandemic on Cancer Care
With Dr. Abdul-Rahman Jazieh
COVID-19 pandemic and Changes in Breast Cancer Management in the UK
With Professor John Robertson
COVID-19 pandemic and Changes in Breast Cancer Management in UK (Q&A)
With Professor John Robertson
OICR Series
Predicting Response to Anthracyclines
Presentation by Dr. Melanie Spears, PhD
Ki67 – is it ready yet?
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
Q&A with Dr. Melanie Spears on the Characterisation of immune “hot” ER+ breast cancer
Q&A with Melanie Spears PhD
SABCS 2021
SABCS 2021 - Updated results from the phase III randomized clinical trial SWOG S1007 (RxPONDER)
Discussion with Dr. Kevin Kalinski, MD, MS
SABSC 2021 - Clinical utility of molecular tumor profiling: Results of SAFIR02-BREAST trial
Discussion with Pr Fabrice André, MD, PhD following his presentation at SABCS 2021
SABCS 2021: EMERALD phase 3 trial, Elacestrant for ER+/HER2- in mBC
SABCS 2021; Discussion with Aditya Bardia, MD, MPH,
ESMO 2021
ESMO 2021 - Overall survival (OS) results from the phase III MONALEESA-2
Discussion with Dr. Gabriel N. Hortobagyi, MD, FACP
ESMO 2021 - KEYNOTE-355: Final results phase III study in mTNBC
Discussion with Prof. Hope S. Rugo, MD
ESMO BREAST 2021 - Breast Cancer Index and prediction of extended endocrine therapy / late relapse
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
ESMO 2021 - HER2-low breast cancer: evolution from primary breast cancer to relapse
Interview with Dr Frederica Miglietta
ASCO 2021
ASCO 2021 - Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Interview with Professor Judy E. Garber MD, MPH
SABCS 2020
SABCS 2020 - Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis
interview with Dr. Wolfgang Janni
SABCS 2020 - First results from a phase III randomized clinical trial SWOG S1007 (RxPonder)
Interview with: Dr. Kevin Kalinsky
SABCS 2020 - 21-Gene Breast Recurrence Score® impact upon physician treatment decision in Quebec
interview with Dr. Saima Hassan
Processes in cancer
AACR 2022: New CAR T-cell Therapy for Solid Tumors
Interview with Pr. John Haanen, MD, Ph.D
All Editorial Videos
ESMO 2024: Dr. Tarek Hijal on Hypofractionated Radiotherapy in Breast Cancer
Dr. Tarek Hijal provides key insights from Day 3 of ESMO 2024, focusing on the latest developments in hypofractionated radiotherapy for breast cancer. He discusses significant findings from the Phase III HypoG-01 trial, led by Dr. Sofia Rivera from Gustave Roussy, France. Dr. Hijal explores how these results are poised to impact breast cancer treatment, particularly in optimizing radiotherapy approaches for better patient outcomes.
ESMO 2024: Prof. Sibylle Loibl Discusses PENELOPE-B Trial Results
Watch as Prof. Sibylle Loibl, PI of the PENELOPE-B trial, presents the final overall survival and subgroup analyses for lobular breast cancer patients at ESMO 2024. Gain a detailed overview of the study's key findings and implications.
ESMO 2024 - Daily RECAP day 3
Dr. Jamil Asselah, along with guests Dr. Kim Ma and Dr. Paolo Tarantino, discuss the morning sessions focused on metastatic and early breast cancer. The panel recaps significant data including insights from the DETECT V trial, KEYNOTE 522, DESTINY-Breast12, and updates from the Natalee trial.
ESMO 2024: Dr. Jean-Philippe Spano - ESMO's Growth and Impact on Oncology Practice
Dr. Jean-Philippe Spano provides a brief history of ESMO's origins and its remarkable growth over the years. He reviews the latest data presented, with a special focus on contributions from his French colleagues and key international studies that have shaped clinical practice in breast cancer oncology.
ESMO 2024: Dr. Cristina Saura: Key ESMO Findings on Breast Cancer Trials & Breastfeeding Safety
Dr. Cristina Saura highlights three key messages from the ESMO 2024 meeting, focusing on significant advancements in breast cancer research. First, the results of the DESTINY-Breast12 trial showcased new treatment options for advanced breast cancer. Second, the ICARUS-BREAST01 study provided further insights into innovative therapeutic approaches. Lastly, she emphasized two groundbreaking international studies that confirmed breastfeeding after breast cancer treatment does not increase the risk of recurrence or new cancers, marking an important step for young survivors seeking safe breastfeeding options.
ESMO 2024: Artificial Intelligence in Oncology with Amy Abernethy, MD, PhD
In this video,Dr. Amy Abernethy highlights the transformative potential of AI in oncology and stresses the need for safety and efficacy in patient care. She outlines three key trends essential for scaling AI in the field.
ESMO 2024: Dr. Erika Hamilton on Trastuzumab and HER2 Testing Insights
In this video, Dr. Erika Hamilton highlights the latest data on trastuzumab and HER2 testing presented at ESMO 2024. She provides valuable insights into recent advancements and their implications for treatment strategies in HER2-positive cancers.
ESMO 2024 - Daily RECAP day 2
In this DailyRECAP for September 15th, Dr. Jamil Asselah returns for a second overview of the day’s breast cancer sessions from ESMO 2024, joined by Dr. Rami Younan and Dr. Kim Ma. They focus on key insights from the Presidential Symposium and practice-changing trials.
ESMO 2024: Updates on ICARUS-BREAST01 with Dr. Barbara Pistilli
Dr. Barbara Pistilli, Head of the Breast Pathology Committee at Gustave Roussy, presents the promising results of the Phase II ICARUS-BREAST01 trial at ESMO 2024.
ESMO 2024 - Overall Survival Data from the KEYNOTE-522 Trial with Dr. Peter Schmid
Dr. Peter Schmid presents the long-awaited overall survival data for Pembrolizumab in early-stage triple-negative breast cancer. His insights provide a crucial update on the impact of this therapy, highlighting significant advancements in treatment outcomes.
ESMO 2024 - Daily RECAP day 1
Join Dr. Asselah, Dr. Younan and Dr. Ma as they review the day's highlights from ESMO 2024
ESMO 2024 - Global Speaker Series - Dr. Nancy Lin on ESMO LBA18: Trastuzumab deruxtecan (T-DXd) in patients with HER2+ advanced/mbc & DESTINYBreast-12 primary results
With Dr. Nancy Lin
ESMO 2024 - Global Speaker Series - Dr. Alnouri Highlights What to Expect at ESMO 2024: Advances in Breast Cancer
with Dr. Anwar Alnouri MD
ESMO 2024 - Global Speaker Series - De-escalation Strategies in HER2+ Early-Stage Breast Cancer with Dr. Carlos A. Gonzalez Nuñez MD
With Dr. Carlos A. Gonzalez Nuñez MD
ASCO 2024 - Global Speaker Series - Dr. Javier Cortés reviews key insights from the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts
Dr. Javier Cortés, Head of the International Breast Cancer Center in Barcelona, Spain, reviews key insights from the recent ASCO meeting, focusing on the PEARLY trial, A-BRAVE, and I-SPY 2.2 abstracts.
ASCO 2024 - Global Speaker Series - Dr. Erika P. Hamilton presents the compelling results from the Phase I trial of H3B-6545
Dr. Erika P. Hamilton delves into the evidence and insights from the trial, highlighting the potential impact on breast cancer treatment.
ASCO 2024 - Global Speaker Series - Exciting update on the overall survival data from the DESTINY-Breast03 trial
Dr. Erika P. Hamilton shares the findings that bring fantastic news for patients with HER2+ breast cancer, showing an impressive improvement in survival by approximately 10 months.
ASCO 20204 - Global Speaker Series - PALMARES-2 Study: Real-World Insights on CDK4/6 Inhibitors
Explore the findings of the PALMARES-2 study with Dr. Claudio Vernieri, offering crucial real-world insights into the efficacy of CDK4/6 inhibitors. Learn how these insights aid clinicians and patients in making informed treatment decisions for specific clinical settings.
ASCO 2024 - Global Speaker Series - Novel Additions to Breast Cancer Therapy: Insights from Dr. Laura Stewart Dominici
Dr. Dominici Chairs ASCO’s "Breast Cancer Local/Regional/Adjuvant" therapy session where 9 abstracts covered a number of different topics, three of which look at some interesting additions to standard therapy.
ASCO 2024 - Global Speaker Series - Advancements in Breast Cancer Research: Insights from Dr. Shaheena Dawood
Dr. Shaheena Dawood shares her excitement about the wealth of information related to patients with breast cancer and how this data will impact clinical practice. In particular, she highlights three crucial pieces of information from ASCO and reviews data from the DESTINY-Breast06 Update, post MONARCH study and updated analysis from the innovaTV207 trial.
ASCO 2024 - Global Speaker Series - Advancements in AI for Breast Cancer Imaging with Dr. Maryellen Giger
Dr. Maryellen Giger discusses the exciting developments in artificial intelligence (AI) applied to breast cancer imaging. From risk assessment to early detection, diagnosis, prognosis, and treatment response, AI is making significant strides
ASCO 2024 - MedTalk: Dr. Stephanie Wong on PARPi Eligibility in Women with Newly Diagnosed Invasive Breast Cancer
Join Dr. Stephanie Wong at ASCO as she presents data on PARP inhibitor eligibility in women with newly diagnosed invasive breast cancer. This research is part of the GREAT AGATA Study, a universal genetic testing initiative aimed at improving patient outcomes.
ASCO 2024 - Global Speaker Series: Dr. Judy-Anne Williams Chapman on Standardizing ER and PgR Quantitation in Breast Cancer
Dr. Judy-Anne Williams Chapman, PhD, emphasizes her four decades of work on the critical topic of estrogen and progesterone receptors. She proposes an adjunctive statistical standardization of quantitated ER and PgR to enhance inter-laboratory comparability of biomarker results and improve the therapeutic management of breast cancer.
ASCO 2024 - Daily RECAP day2
Join Dr. Jamil Asselah and Dr. Kim Ma, along with Dr. Véronique Diéras, as they review the day's highlights with a special focus on the positive findings from the DESTINY-Breast06 trial. They will discuss how these results are set to impact clinical practice, particularly for patients with HER2-ultralow breast cancer, and delve into all aspects of T-DXd in treatment strategies.
ASCO 2024 - Dr. Jane Lowe Meisel Presents I-SPY2.2 Trial Results on Datopotamab Deruxtecan for High-Risk HER2-Negative Breast Cancer
Join Dr. Jane Lowe Meisel as she presents the first results from the I-SPY2.2 trial at ASCO. This study explores the use of datopotamab deruxtecan as part of neoadjuvant therapy for high-risk, HER2-negative early-stage breast cancer.
ASCO 2024 - Dr. Matthew P. Goetz on the ELAINE 3 Study: Lasofoxifene and Abemaciclib in ER+/HER2- Advanced Breast Cancer
Join Dr. Matthew P. Goetz as he discusses the open-label, randomized, multicenter phase 3 ELAINE 3 study. This research investigates the efficacy and safety of lasofoxifene combined with abemaciclib for treating ER+/HER2- locally advanced or metastatic breast cancer with an ESR1 mutation. Discover the potential impact of these findings on patient care and treatment options.
ASCO 2024 - Dr. Jean-Pierre Ayoub Reviews DESTINY-Breast06: Trastuzumab Deruxtecan's Impact on Progression-Free Survival
Join Dr. Jean-Pierre Ayoub as he reviews important results from the DESTINY-Breast06 trial. Learn how Trastuzumab Deruxtecan significantly improves progression-free survival in breast cancer patients previously treated with endocrine therapy. Discover the potential implications of these findings for patient care and treatment strategies.
ASCO 2024 - Dr. Nagi S. El Saghir on New Advances in Sequencing CDK4/6 Inhibitors with Endocrine Therapy in Advanced Breast Cancer
Join Dr. Nagi S. El Saghir as he discusses new studies presented at ASCO 2024. He highlights recent studies on the sequencing of CDK4/6 inhibitors and endocrine therapy in patients with advanced breast cancer.
ASCO 2024 - Dr. Mark Basik Highlights TRICIA Study Results in Triple Negative Breast Cancer
Join Dr. Mark Basik as he presents the results of the TRICIA study, conducted across cancer centers and hospitals in Quebec and Ontario. Learn about the significant findings and the plans to initiate a clinical trial in the coming years, with the goal of advancing treatment options for this challenging type of cancer.
ASCO 2024: Daily RECAP day 1 with Drs. Asselah and Ma
Join Drs. Asselah and Ma as they review the key takeaways from Day 1 of ASCO. They delve into hormone-positive disease, discuss notable abstracts, and provide insights on the Flex trial registry. Hear about Dr. Grace Choong’s research from Mayo Clinic on endocrine therapy for ER-low breast cancer patients. Stay tuned for what to expect in the days ahead at the conference.
ASCO 2024 : Global Speaker Series with Dr. Nuñez
Watch Dr. Carlos A. Gonzalez Nuñez discuss "De-escalation studies: The Next Step in Early Breast Cancer" in this brief video from the ASCO Meeting
ASCO 2024 : Global Speaker Series with Dr. Conte
Join Dr. Pier Franco Conte as he discusses the A-BRAVE trial, a Phase III randomized study exploring the use of avelumab in early triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy or those at high risk following primary surgery and adjuvant chemotherapy.
ASCO 2024 : Global Speaker Series with Dr. Santa Maria
Join Dr. Santa Maria as he discusses his current project exploring the use of chemotherapy combined with immunotherapy in patients with stage 2 and 3 triple-negative breast cancer. Learn how early PET scan changes are being used to identify patients who achieve a complete pathologic response earlier in the treatment process.
SABCS 2023 : Global Speaker Series Dr. Sara A. Hurvitz
HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
SABCS 2023 : Global Speaker Series Dr. Seema Khan
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
SABCS 2023 : Global Speaker Series Dr. Peter Schmid
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
SABCS 2023 : Global Speaker Series Dr. Hope S. Rugo
Essential findings of the INAVO120 primary analysis
SABCS 2023 : Global Speaker Series Dr. Shaheenah Dawood
Exploring Pioneering Initiatives: Tailoring Patient-Centric Solutions for a Diverse Cohort in the UAE
SABCS 2023 : Global Speaker Series Dr. Hatem Azim
Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy
SABCS 2023 : MedTalk Dr. Nagi S. El Saghir
Insights from the RIGHT Choice trial
SABCS 2023 : MedTalk Dr. Paolo Tarantino
Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
SABCS 2023 : Global Speaker Series Dr. Anne May
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
SABCS 2023 : Daily RECAP Day 4 - December 8th
Daily Review from SABCS 2023 with Dr. Jamil Asselah, Dr. Esfahani, and Dr. Tarantino.
SABCS 2023 : MedTalk Dr. Julie Lemieux
Neoadjuvant chemotherapy in invasive lobular carcinoma of the breast: A retrospective study on survival outcomes
SABCS 2023 : MedTalk Dr. Jean-Pierre Ayoub
Prognostic Impact of Adjuvant Trastuzumab for the Treatment of Localized Stage I Breast Cancer - Single Tertiary Center Experience
SABCS 2023 : Daily RECAP Day 3 Part 2 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Daily RECAP Day 3 Part 1 - December 7th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : MedTalk Dr. Stephanie Wong
Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer
SABCS 2023 : MedTalk Dr. Mark Basik
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
SABCS 2023 : Global Speaker Series Dr. Eleftherios (Terry) P. Mamounas
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
SABCS 2023 : Daily Recap, December 6th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS 2023 : Global Speaker Series Dr. Claudio Vernieri
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
SABCS 2023 : MedTalk Nathalie Bolduc
Key points from the SABCS session on Prevention, early detection and interception
SABCS 2023 : Global Speaker Series Barbarra Segara
Screening for health related social needs, and now what? With Barbara Segarra-Vasquez DHSc
SABCS 2023 : Global Speaker Series Dr. Carlos A. Gonzalez Nuñez
Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL
SABCS 2023 : Daily Recap, December 5th
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
SABCS - T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2+ MBC
Discussion with Dr. Sara Hurvitz, M.D.
SABCS - Racial Disparity in Pro-metastatic T-MEM Among Women With Residual BC After NAC
Discussion with Dr. Maja H. Oktay, M.D., Ph.D.
SABCS 2022 - Camizestrant May Be Superior to Fulvestrant in Patients With HR+/HER2- BC
Discussion with Dr. Mafalda Oliveira, M.D., Ph.D.
SABCS 2022 : Genetic Profiling (POLAR) for Patients with BC may Safely Omit Radiation
Discussion with Pr. Per Karlsson, M.D.
SABCS 2022 - Race and Clinical Outcomes in the RxPONDER Trial
Discussion with Dr. Yara Abdou
ESMO 2022 - TROPiCS-02: Final results phase III study in MBC
Discussion with Prof. Hope S. Rugo, MD
ASCO 2022 - MAINTAIN Trial of Fulvestrant/Exemestane +/- Ribociclib After Progression in mBC
Discussion with Dr. Kevin Kalinski, MD, MS
ASCO 2022 - DESTINY-Breast04 trial in HER2-low unresectable and/or metastatic breast cancer
Pr. John Bartlett and Pr. David Cameron, MD, review the current results of DESTINY-Breast04 trial
AACR 2022: Recurrent NIB May Not Always Be Related to the Primary Lesion
Interview with Dr. Tanjina Kader, PhD
AACR 2022: AI Model Can Help Predict Adverse Events from New Drug Combinations
Interview with Pr. Bart Westerman, PhD
AACR 2022: New CAR T-cell Therapy for Solid Tumors
Interview with Pr. John Haanen, MD, Ph.D
CLINICAL IMPACT SERIES: SABCS 2021 - Breast Cancer Review Expert Panel Discussion
Presentations review with Dr. Jean-Pierre Ayoub, MD, FRCPC, Dr. Rami Younan, MD, FRCSC, and Dr. Jamil Asselah, MD, FRCPC
SABCS 2021 - Updated results from the phase III randomized clinical trial SWOG S1007 (RxPONDER)
Discussion with Dr. Kevin Kalinski, MD, MS
SABSC 2021 - Clinical utility of molecular tumor profiling: Results of SAFIR02-BREAST trial
Discussion with Pr Fabrice André, MD, PhD following his presentation at SABCS 2021
SABCS 2021: EMERALD phase 3 trial, Elacestrant for ER+/HER2- in mBC
SABCS 2021; Discussion with Aditya Bardia, MD, MPH,
AI SERIES: Retrospective Overview Panel Discussion
Panel discussion with Faculty with Pr. Evelyne Yehudit Bischof, Professor Robert Clarke, Professor John FR Robertson
AI SERIES: Panel Discussion - Precision medicine in practice - diagnostic algorithms & geroncology
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
ESMO 2021 - Overall survival (OS) results from the phase III MONALEESA-2
Discussion with Dr. Gabriel N. Hortobagyi, MD, FACP
ESMO 2021 - KEYNOTE-355: Final results phase III study in mTNBC
Discussion with Prof. Hope S. Rugo, MD
AI SERIES - Panel Discussion: A review of Precision medicine in cancer therapeutics - Hormone sensitive Breast Cancer and AI challenges
Discussion on Presentation by Professor John FR Robertson MD
AI SERIES - Panel Discussion: AI assisted drug development and repurposing in Breast Cancer
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Personalized vs precision medicine, clinical applicability
Discussion on Presentation by Dr. Evelyne Yehudit Bischof
AI SERIES - Panel discussion: Do we need Artificial Intelligence for Precision Medicine?
Discussion on Presentation by Pr. Robert Clarke
ASCO 2021 - Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Interview with Professor Judy E. Garber MD, MPH
Ki67 – is it ready yet?
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
ESMO BREAST 2021 - Breast Cancer Index and prediction of extended endocrine therapy / late relapse
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
ESMO BREAST 2021 - HER2-low breast cancer - what is it anyway?
Interview with Professor John M.S. Bartlett BSc, PhD, FRCPath
Q&A with Dr. Melanie Spears on the Characterisation of immune “hot” ER+ breast cancer
Q&A with Melanie Spears PhD
ESMO 2021 - HER2-low breast cancer: evolution from primary breast cancer to relapse
Interview with Dr Frederica Miglietta
Primary outcome analysis of invasive disease-free survival for monarchE a Quebec perspective
Interview with Dr Rami J. Younan
A Quebec clinical perspective of the randomized clinical trial SWOG S1007 (RxPonder)
Interview with Dr Jean-Francois Boileau
Expected medium- and long-term impact of the COVID-19 on Breast Cancer Treatment in Quebec
Interview with Dr Jamil Asselah
SABCS 2020 - Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis
interview with Dr. Wolfgang Janni
SABCS 2020 - First results from a phase III randomized clinical trial SWOG S1007 (RxPonder)
Interview with: Dr. Kevin Kalinsky
SABCS 2020 - 21-Gene Breast Recurrence Score® impact upon physician treatment decision in Quebec
interview with Dr. Saima Hassan
SABCS 2020 - Primary outcome analysis of invasive disease-free survival for monarchE
With Dr. Priya Rastogi
ESMO 2020 - Q&A with Professor Stephen Johnston on results from MonarchE
with Professor Stephen Johnston
ESMO-2020 - Q&A with Dr. Susana Benerjee - The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration
With Dr. Susana Benerjee
ESMO-2020 Q&A with Professor Guy Jerusalem on Expected medium and long-term impact of the COVID-19 outbreak in Oncology
with Professor Guy Jerusalem
COVID-19 pandemic and Changes in Breast Cancer Management in UK (Q&A)
With Professor John Robertson